Progressive Multifocal Leukoencephalopathy News and Research

RSS
Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

Genetic modification in ‘coat’ of fatal brain virus may allow it to escape antibodies

IL-21 protein is a major part of immune response to chronic infections in the central nervous system

IL-21 protein is a major part of immune response to chronic infections in the central nervous system

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Study of MS patients shows 18% were given wrong diagnoses

Study of MS patients shows 18% were given wrong diagnoses

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

New first-line treatment for peripheral T-cell lymphoma approved by FDA

New first-line treatment for peripheral T-cell lymphoma approved by FDA

FDA approves new drug to treat MS in pediatric patients

FDA approves new drug to treat MS in pediatric patients

Extending dosing intervals makes common multiple sclerosis drug safer to use

Extending dosing intervals makes common multiple sclerosis drug safer to use

TSRI scientists shed light on molecular workings of MS drug

TSRI scientists shed light on molecular workings of MS drug

Penn State researchers link mutation in common virus to fatal brain disease

Penn State researchers link mutation in common virus to fatal brain disease

Rituximab outperforms fingolimod after natalizumab switch

Rituximab outperforms fingolimod after natalizumab switch

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Natalizumab shows relapse prevention benefits over fingolimod in MS

Natalizumab shows relapse prevention benefits over fingolimod in MS

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Interim data from long-term extension Tecfidera® (dimethyl fumarate) study

Researchers reveal potential new treatment methods for fatal brain disease

Researchers reveal potential new treatment methods for fatal brain disease

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Shorter washout period during transition from natalizumab supported

Shorter washout period during transition from natalizumab supported

Better treatment, prevention strategies still needed for opportunistic infections related to AIDS

Better treatment, prevention strategies still needed for opportunistic infections related to AIDS

Study: Extending natalizumab treatment effective in preventing MS symptoms

Study: Extending natalizumab treatment effective in preventing MS symptoms